MAS — Masco Corporation

The market is split: Q2 2026 adjusted EPS of $1.64 beat estimates and management raised FY26 adjusted EPS guidance to $4.40-$4.60, but reported revenue of $1.99B missed consensus on still-soft R&R demand. The stock has pulled back roughly 9% over the past 30 days, RSI is middling at 43.4, and the analyst base skews Buy/Hold rather than strongly bullish, so sentiment is balanced rather than euphoric.

Revenue has been flat-to-declining: Q2 2026 revenue was $1.99B, down 2.9% YoY, following Q3/Q4 2025 declines of 3.3%/1.9%, with Q1 2026 the only recent positive at +6.5%. The top-line pattern is a slow grind lower rather than a sharp collapse. Earnings are inflecting up on margin rather than sales: Q2 2026 operating margin jumped to 23.6% vs 20.1% a year ago and 19.0% in Q2 2024, helping diluted EPS rise from $1.17 in Q2 2024 to $1.28 in Q2 2025 to $1.60 in Q2 2026. The margin jump includes tariff refunds and restructuring/timing benefits, so the beat is not as clean as the headline suggests; TTM operating margin is ~17.7%.

At $72.80 as of 2026-08-27, MAS trades at 16.7x trailing EPS and about 16.1x next-fiscal-year consensus EPS of $4.53, below its 5-year average P/E of 21.6x. PEG is 1.16x, and P/S of 1.88x is roughly in line with the 1.80x 5-year average. That is fair-to-cheap for a high-ROIC, cash-generative business, though the discount partly reflects stagnant revenue and negative equity from heavy buybacks. Analyst consensus target of $82.4 implies modest upside.

As of 2026-08-27, the stock is down from the low-$80s even though forward EPS estimates were raised, so the market is pricing in either temporary margin strength or continued top-line weakness. At ~16x forward earnings, the stock is not priced for growth; if R&R volumes simply stabilize and margins hold, there is re-rating room toward MAS's historical 20x-plus multiple. If margin reverts as tariff refunds fade and revenue keeps declining, current EPS could be near the peak and $72.80 would not be obviously cheap.

As of 2026-08-27, RSI was 43.38, mid-range with a weak tone; price was -2.26% below the 20-day SMA, -4.85% below the 50-day SMA, and +5.08% above the 200-day SMA. That is a short/medium-term pullback inside a longer-term uptrend, not an oversold bottom or confirmed breakdown. For entry timing, the stock likely needs to reclaim the 20-day or hold the 200-day before momentum turns.

• High mortgage rates keep housing turnover low; this supports maintenance/repair spending but suppresses discretionary remodeling projects.
• North American repair & remodel (R&R) volumes remain flat-to-negative, directly pressuring top-line growth.
• Tariff/trade policy has been a near-term tailwind via refunds, but also creates input-cost volatility, especially petrochemicals.
• Consumer confidence and big-ticket DIY spending are cautious, limiting pricing power.
• Capital returns are supported by strong free cash flow but constrained by negative book equity.

• Q3 2026 earnings in late October 2026: any sign that revenue is returning to positive growth after two years of softness would be a major re-rating trigger.
• Behr's 2027 Colour of the Year campaign and Habitat for Humanity partnership, plus a new CMO, could reaccelerate paint/DIY engagement.
• Completion of the $300M ASR and ongoing $2B buyback authorization support EPS and FCF yield.
• A Fed rate-cut cycle that boosts housing turnover would directly lift the R&R outlook.

• Revenue has declined YoY in 3 of the last 4 reported quarters; if demand stays weak, margin-driven EPS growth will fade.
• Q2 2026's 23.6% operating margin was flattered by tariff refunds and one-off efficiencies; normalized margins are likely lower.
• Negative stockholders' equity (-$365M) and $3.2B long-term debt limit balance-sheet flexibility, though cash flow covers it.
• Input cost inflation and FX/tariff shifts could squeeze gross margin.
• Buyback-heavy capital returns cannot offset a prolonged top-line downturn forever.

Masco is a high-quality, cash-generative franchise with strong margin discipline, trading at a meaningful discount to its own history. The main issue is top-line: R&R spending has been soft for over a year and Q2 2026 still showed -2.9% revenue growth. At ~16x forward earnings and a roughly 10% trailing FCF yield, the risk/reward is attractive for a patient investor, but the stock likely stays range-bound until revenue inflects.

I applied an 18.0x multiple to next-fiscal-year consensus EPS of $4.53, a discount to MAS's 21.6x 5-year average P/E but a premium to the current 16.7x trailing multiple, reflecting flat revenue offset by high ROIC and strong cash generation. This yields $81.54, rounded to $81.50, and is broadly consistent with a ~12x EV/EBITDA view and the recent analyst target range.